mission

We protect people’s lives and health, bringing the world’s best technologies to everyone

About

News

06.10.2025 Nanolek and Gazprombank agreed to cooperate

15.09.2025 Nanolek сompletes сlinical trial of HPV vaccine in сhildren

11.06.2025 The results of a clinical trial of the first Russian HPV vaccine were presented to the medical community

16.05.2025 Nanolek celebrated its birthday by organising a sports festival for the residents of Lyovintsevo

14.05.2025 Availability of domestic vaccines is a matter of national security

28.04.2025 Evgeny Barinov takes part in the forum for leaders, CEOs, and HR directors "The New Reality of Management"

11.04.2025 The Russian Ministry of Health authorised a phase III clinical trial of a new pneumococcal vaccine

31.03.2025 Nanolek received a registration certificate for the first Russian vaccine against human papillomavirus

24.02.2025 Gennady Schweigert and Pavel Mileiko acquire 50% stake in Nanolek LLC

Vaccines

Numbers

Nanolek ranks among the top-10 suppliers in Russia’s pharmaceutical public-procurement market.

Headway Rating ↗

About

25.3

billion rubles

the company's turnover in 2024

the average

annual rate of growth in 2020-2024

200

million

tablets have been produced since 2014 — enough to lay a road from Kirov to the “Vostok” Antartic station

million

children in Russia have already been immunized with vaccines produced by “Nanolek”

Plant

At the innovative Nanolek Plant in the Kirov region medicines are produced according to international GMP* standards

Drugs for the treatment of cancer

Brukinza

Zanubrutinib is a selective low—molecular-weight inhibitor of Bruton tyrosine kinase, an oncohematological drug

Darzalex

Daratumumab is a monoclonal antibody that acts on the CD38 surface protein

Lomustine

Lomustin is an antitumor drug of alkylating action

Stibevara

Bevacizumab is a recombinant hyperchymeric monoclonal IgG1 antibody

Tretinoin

Drugs for the treatment of orphan diseases

Hunterase

Iduronate-2-sulfatase is a drug for enzyme replacement therapy for Hunter syndrome

R&D

Nanolek’s own R&D center was opened in 2021 in the science city of Pushchino. In 2024 it was relocated to the Biomedical Complex (BMC) in Kirov and transformed into the Scientific and Practical Center for Pharmaceutical Development. Here, new vaccines are created “from scratch”— from active-substance design to preparing samples for pre-clinical and clinical studies and subsequent production scale-up.

The journey of a medicine from molecule to market can take up to ten years. Early development of a single molecule lasts from one to two years, and on average only ten out of one hundred researched molecules reach the market.

The Scientific and Practical Center occupies 300 m² and is fully equipped for vaccine development and production, including high-tech laboratory and pilot equipment for producing trial and pilot-industrial batches of vaccine antigens.